- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Segment 3 - Provider Buy-in and Clinical Pathway Development
Dr Yu said that it is crucial for providers' voices to be heard in pathway development.
Dr Yu said that it is crucial for providers’ voices to be heard in pathway development.
“If you’re going to be successful, you need to have buy-in. If you need to have buy-in, you need to have people believe that it’s a transparent process of pathways development that they respect and feel that they had a voice in,” he explained.
He detailed how a healthcare setting can also impact pathway development, and the role that published medical literature has on the real-world setting practice. The actual experience of implementing pathways and patient behavior need to be closely monitored. There should also be feedback loops that include physicians.
Dr Tischler agreed, saying that provider buy-in is necessary. He said that for authentic buy-in, one cannot force a caregiver to act or practice in a certain way.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
